ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
A Simplified Three-Tailed N-Alkyl Phosphoramidate Lipid Platform Enables Inguinal Adipose-Accumulated mRNA Delivery for Anti-Obesity Therapy.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Simplified Three-Tailed N-Alkyl Phosphoramidate Lipid Platform Enables Inguinal Adipose-Accumulated mRNA Delivery for Anti-Obesity Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Obesity is a complex metabolic disorder associated with an increased risk of type 2 diabetes, cardiovascular diseases, and metabolic dysfunction-associated steatotic liver disease. While protein-based therapies like glucagon-like peptide-1 (GLP-1) receptor agonists (e.g., semaglutide) and fibroblast growth factor 21 (FGF21) analogs show promise, their clinical utility is limited by poor tissue targeting and the need for frequent high-dose injections. To overcome these challenges, we develop an mRNA-based therapy encoding a long-acting GLP-1/FGF21 fusion protein (mGLP-1/FGF21), engineered with an IgG4 Fc domain to enhance stability. For adipose tissue-specific delivery, we design a three-tailed N-alkyl phosphoramidate lipid (NPL) formulation with enhanced fluidity in lipid-rich microenvironments, promoting membrane fusion and endosomal escape to significantly improve adipocyte transfection efficiency. Systematic optimization reveals that removing DOPE (while retaining cholesterol) enhanced delivery efficiency 5-fold compared to conventional four-component Lipid Nanoparticle (LNP), without inducing metabolic burden or inflammation upon repeated dosing. The optimized platform effectively delivers mGLP-1/FGF21, demonstrating potent anti-obesity effects in mice through synergistic GLP-1 and FGF21 signaling. Treatment induces significant reductions in body weight and fat mass while preserving lean mass and ameliorating hepatic steatosis. By combining adipose-accumulated mRNA delivery with dual-hormone therapy, this study presents a novel and localized strategy for obesity treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.